Delivery Order SPE2DB22D2006-SPE2DB25FW4BP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of HAVRIX 1,440 Unit/ML Syringe vaccines valued at $1,339.10. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The order is scheduled for completion by August 7, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a delivery order valued at $1,597.88 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringes. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes a firm fixed price structure with no set-aside designation. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's...
- The Defense Logistics Agency awarded a $11,463.02 delivery order to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine syringes on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes, with a ceiling value of $1,012.20 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,523.83 to AmerisourceBergen Drug Corp for the supply of 1,440 units of Havrix vaccine (1 ml syringes) with a completion date of June 30, 2025. This firm fixed-price contract, awarded on June 27, 2025, with no set-aside designation, will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a competitive award to a critical pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes valued at $5,671.48 with a firm fixed price structure. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of HAVRIX 1,440 Unit/ML syringe vaccine. This firm fixed-price, non-set-aside delivery order has a ceiling value of $8,069.00 and an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of HAVRIX 1,440 Unit/mL vaccine syringes, with a ceiling value of $8,148.75. This is a firm fixed price delivery order with no set-aside designation, placing performance in Conshohocken, Pennsylvania, and scheduled for completion by August 15, 2025. The award represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a $1,417.08 delivery order to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes, with an ultimate completion date of July 14, 2025. This firm fixed-price contract, awarded on July 11, 2025, is non-set-aside and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4BPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of 1,440 units of Havrix 1,440 Unit/ML syringe vaccine product. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $47,143.80 and is scheduled for completion by September 10, 2025. The award was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. No set-aside designation was applied to this award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. As a child contract under the SPE2DX IDC, this delivery order exemplifies AmerisourceBergen's role in supplying pharmaceutical products and medical commodities to support defense healthcare requirements globally. The company's extensive federal contract portfolio demonstrates consistent performance in fulfilling competitively awarded medical supply needs across multiple therapeutic domains, including vaccines, specialty medications, and medical devices. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative, under which this contract vehicle operates, leverages AmerisourceBergen's capabilities to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with flexible, comprehensive pharmaceutical support.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $47.1k | 9/9/25 |